FSP1:是铁灭菌的一个关键调节剂
Wentao Li1, Lin Liang2, Siyi Liu2
1Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, Hunan 410008, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan 410011, China.
Trends in molecular medicine
|June 25, 2023
概括
铁酶抑制蛋白1 (FSP1) 通过FSP1-CoQ10-NAD(P) H轴和维生素K循环调节铁酶. FSP1影响恶性瘤的预后和治疗,使其对理解铁灭症至关重要.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 铁灭菌抑制蛋白1 (FSP1) 是铁灭菌的一个关键调节剂.
- FSP1通过FSP1辅酶Q10 (CoQ10) -NAD(P) H轴和维生素K氧化还原循环运作.
- FSP1活动受到转录因子,ncRNA和表观遗传修饰等上游因素的影响.
研究的目的:
- 综合审查FSP1在ferroptosis调节中的作用.
- 总结FSP1的监管途径和机制.
- 探索FSP1,疾病预后和治疗之间的关联.
主要方法:
- 关于FSP1在铁亡中的作用的文献综述.
- 对FSP1监管途径的分析.
- 检查FSP1在恶性瘤中的临床意义.
主要成果:
- 通过特定的生物化学途径,FSP1是铁亡的关键调节者.
- 上游调节因素和表观遗传修饰影响FSP1的功能.
- FSP1与恶性瘤和治疗策略的预后不佳有关.
结论:
- 在ferroptosis中,FSP1起着至关重要的作用,影响疾病的进展.
- 了解FSP1监管对于开发新的癌症治疗方法至关重要.
- FSP1代表了与铁死相关疾病的有前途的治疗标.
相关概念视频
01:16Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
02:58Regulated Protein Degradation
2.6K
2.6K
01:31Regulation of the Unfolded Protein Response
2.5K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K